KISPLYX 4 mg, hard capsule 30 capsules
Active ingredients: Lenvatinib, Lenvatinib mesylate
Commercialized according to BDPMDispensing in France: Prescription only
Hard capsule30 capsulesorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- KISPLYX 4 mg, gélule
- Pharmaceutical form
- gélule
- Route of administration
- orale
- Presentation description
- plaquette(s) polyamide aluminium PVC-Aluminium de 30 gélule(s)
- Marketing authorisation holder
- EISAI (ROYAUME-UNI)
- Reimbursement according to BDPM
- 100%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 14 Feb 2023
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
67913602CIP73007495CIP133400930074954Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| LENVATINIBgélule | 4 mg · une gélule | FT |
| MÉSILATE DE LENVATINIBgélule | — | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The published catalog does not list other packages of similar medicines.